Wednesday, August 12, 2026
20.8
C
Bengaluru
Hot topics
IMS Health Market Reflection Report for September 2016
The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.
Digital Noise to Digital Voice – A 4-Module Workshop for Pharma People
https://www.youtube.com/watch?v=BOO_CNxEzwQ
When Covid19 struck for the first time in March 2020, the...
Going Digital – What Indian Pharma C-Suite has to Say
Any transformational initiative must be driven by the CEO...
Astra Zeneca Tops Indian Pharma in New Introductions 2024
Analysis of Indian Pharmaceutical Market (IPM) – 2024
This data...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Hot topics
Creat Customer
Articles by K. Hariram, Hanno Wolfram, Vivek Hattangadi, Salil Kallianpur, Amit Jain, Dr. Palakodeti Ratnakar, and Pankaj Mehrotra
MedicinMan Indian Pharma Digital Adoption Survey
Smaller Indian pharma companies bore the strongest impact from...
MedicinMan Steps into Year Five
Articles by K. Hariram, Daxesh Patel, Gopal Kishore, Amit Jain, Sunil Bajaj and Vivek Hattangadi
Pharma Marketing & The Reinvention
Introducing the top 10 companies in top 10 therapy areas according to statistics published by AIOCD
Indian Pharmaceutical Innovation – Post TRIPS
It is the twentieth anniversary of the new patent act in January 2025. The post-patent (P20) era is a story of resilience, determination, and charting a course that set global ambitions, a story of finding opportunity in adversity. It is a story for case studies in business schools, in international studies, in global health efforts.
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025
1. Market Overview
The oncology sector remains the most dominant...
Newsletter
Get important news delivered directly to your inbox and stay connected!